Calm Novo Nordisk following Brexit: We had five years to prepare

Denmark's most valuable company does not find cause to worry over brexit. "We have laid plans for every situation imaginable."

Photo: Novo Nordisk / PR

Novo Nordisk has prepared for every single scenario, for which reason Brexit will hardly have a major impact. At least not now, according to Denmark's most valuable company. Just before Christmas, a deal was finally settled between the EU and the UK after nearly five years of negotiations.

"We have spent the last five years preparing for Brexit, and we have laid plans for every situation imaginable. Our British medical stocks have increased, and we have secured further shipment capacity in order to maintain the supply chain to the UK. Adding to that, we're collaborating closely with the UK government and health and social care department to ensure that patients' interests are made a priority," states Novo Nordisk's Global Public Affairs & Patient Relations Vice President Troels Rye-Andersen in a comment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs